Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli
Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis and E. coli infections after development partner Naval Medical Research Center (NMRC) requested a pre-IND....
https://smallcaps.com.au/immuron-naval-medical-research-center-develop-novel-oral-therapeutic-e-coli/
Filter by Year:
- Immuron (ASX:IMC) develops research agreement
- Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
- Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli
- Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment
- Immuron (ASX:IMC) reveals positive anti-diarrhoea vaccine results
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
